| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8771739 | MAYNE PHARMA | Pharmaceutical compositions for poorly soluble drugs |
Jul, 2023
(9 months ago) | |
| US9713642 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US10806792 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US10463740 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US8921374 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US9272046 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
Tolsura is owned by Mayne Pharma.
Tolsura contains Itraconazole.
Tolsura has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Tolsura are:
- US8771739
Tolsura was authorised for market use on 11 December, 2018.
Tolsura is available in capsule;oral dosage forms.
Tolsura can be used as treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis.
The generics of Tolsura are possible to be released after 21 June, 2033.
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 11 December, 2018
Treatment: Treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis
Dosage: CAPSULE;ORAL
TOLSURA family patents
